Positive News SentimentPositive NewsNASDAQ:ASLN ASLAN Pharmaceuticals (ASLN) Stock Forecast, Price & News $2.01 +0.02 (+1.01%) (As of 09/22/2023 08:51 PM ET) Add Compare Share Share Today's Range$2.01▼$2.0650-Day Range$1.96▼$2.8452-Week Range$1.70▼$4.69Volume1,400 shsAverage Volume74,595 shsMarket Capitalization$32.86 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ASLAN Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside679.4% Upside$15.67 Price TargetShort InterestHealthy1.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.01) to ($3.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector484th out of 962 stocksPharmaceutical Preparations Industry216th out of 448 stocks 3.5 Analyst's Opinion Consensus RatingASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.67, ASLAN Pharmaceuticals has a forecasted upside of 679.4% from its current price of $2.01.Amount of Analyst CoverageASLAN Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.77% of the float of ASLAN Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverASLAN Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ASLAN Pharmaceuticals has recently decreased by 20.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldASLAN Pharmaceuticals does not currently pay a dividend.Dividend GrowthASLAN Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASLN. Previous Next 3.1 News and Social Media Coverage News SentimentASLAN Pharmaceuticals has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ASLAN Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ASLN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added ASLAN Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.69% of the stock of ASLAN Pharmaceuticals is held by insiders.Percentage Held by Institutions42.23% of the stock of ASLAN Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ASLAN Pharmaceuticals are expected to decrease in the coming year, from ($3.01) to ($3.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ASLAN Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ASLAN Pharmaceuticals is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioASLAN Pharmaceuticals has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ASLAN Pharmaceuticals (NASDAQ:ASLN) StockASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Read More ASLN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASLN Stock News HeadlinesSeptember 22, 2023 | finance.yahoo.comASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology CongressSeptember 7, 2023 | finance.yahoo.comASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 25, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 14, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aslan Pharmaceuticals (ASLN)August 11, 2023 | msn.comIndexes Mixed After Economic Data; Walmart Rises On Analyst Upgrade As Earnings LoomAugust 11, 2023 | finance.yahoo.comASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 7, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Aslan Pharmaceuticals (ASLN)July 6, 2023 | msn.comAslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatmentSeptember 25, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.July 6, 2023 | finance.yahoo.comWhat's Going On With ASLAN Pharmaceuticals Stock Today?July 6, 2023 | finance.yahoo.comEblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic DermatitisJuly 5, 2023 | finance.yahoo.comASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic DermatitisJune 26, 2023 | msn.comHC Wainwright & Co. Reiterates ASLAN Pharmaceuticals Ltd - ADR (ASLN) Buy RecommendationJune 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN) and Roivant Sciences (ROIV)June 23, 2023 | finance.yahoo.comASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic DermatitisJune 22, 2023 | benzinga.comASLAN Inks Licensing Deal With Zenyaku Kogyo To Commercialize Eblasakimab In JapanJune 22, 2023 | finance.yahoo.comASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in JapanJune 14, 2023 | markets.businessinsider.comPiper Sandler Remains a Buy on Aslan Pharmaceuticals (ASLN)June 4, 2023 | msn.comAsian Equities Rebound in Thursday TradingJune 1, 2023 | finance.yahoo.comASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 31, 2023 | msn.comRoth MKM Initiates Coverage of ASLAN Pharmaceuticals Ltd - ADR (ASLN) with Buy RecommendationMay 18, 2023 | finance.yahoo.comASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia AreataMay 15, 2023 | finance.yahoo.comASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology MeetingApril 29, 2023 | msn.comHC Wainwright & Co. Maintains ASLAN Pharmaceuticals Ltd - ADR (ASLN) Buy RecommendationApril 28, 2023 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 28, 2023 | finance.yahoo.comASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 24, 2023 | finance.yahoo.comASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology MeetingSee More Headlines Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ASLN Company Calendar Last Earnings8/11/2023Today9/24/2023Next Earnings (Estimated)10/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASLN CUSIPN/A CIK1722926 Webwww.aslanpharma.com Phone65-6817-9598Fax65-6225-2419Employees34Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.67 High Stock Price Forecast$17.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+679.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,380,000.00 Net MarginsN/A Pretax Margin-385.37% Return on Equity-397.58% Return on Assets-74.46% Debt Debt-to-Equity Ratio3.84 Current Ratio2.26 Quick Ratio2.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book3.35Miscellaneous Outstanding Shares16,350,000Free Float15,583,000Market Cap$32.86 million OptionableNot Optionable Beta1.76 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Carl Alan Jason Morton Firth EMBA (Age 50)Ph.D., Founder, CEO & Exec. Director Mr. Kiran Kumar Asarpota (Age 44)COO & Head of Fin. Mr. Ben Goodger (Age 60)Gen. Counsel Mr. Stephen Doyle (Age 50)Chief Bus. Officer Dr. Alexandre Kaoukhov M.D. (Age 49)Chief Medical Officer Charlie HsuInvestor Relations DirectorChi-Chin WangIR & Corp. Devel. DirectorMore ExecutivesKey CompetitorsRegulus TherapeuticsNASDAQ:RGLSBeyondSpringNASDAQ:BYSINuCanaNASDAQ:NCNAPieris PharmaceuticalsNASDAQ:PIRSRain OncologyNASDAQ:RAINView All CompetitorsInstitutional OwnershipBVF Inc. ILBought 1,049,999 shares on 8/15/2023Ownership: 6.422%Citadel Advisors LLCBought 100 shares on 8/15/2023Ownership: 0.000%Schonfeld Strategic Advisors LLCBought 54,400 shares on 8/14/2023Ownership: 0.333%Renaissance Technologies LLCSold 12,240 shares on 8/11/2023Ownership: 0.176%View All Institutional Transactions ASLN Stock - Frequently Asked Questions Should I buy or sell ASLAN Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASLN shares. View ASLN analyst ratings or view top-rated stocks. What is ASLAN Pharmaceuticals' stock price forecast for 2023? 3 analysts have issued 1 year target prices for ASLAN Pharmaceuticals' stock. Their ASLN share price forecasts range from $15.00 to $17.00. On average, they predict the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 679.4% from the stock's current price. View analysts price targets for ASLN or view top-rated stocks among Wall Street analysts. How have ASLN shares performed in 2023? ASLAN Pharmaceuticals' stock was trading at $1.80 at the beginning of 2023. Since then, ASLN stock has increased by 11.7% and is now trading at $2.01. View the best growth stocks for 2023 here. Are investors shorting ASLAN Pharmaceuticals? ASLAN Pharmaceuticals saw a drop in short interest in August. As of August 31st, there was short interest totaling 244,500 shares, a drop of 20.8% from the August 15th total of 308,900 shares. Based on an average trading volume of 124,400 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.8% of the shares of the company are sold short. View ASLAN Pharmaceuticals' Short Interest. When is ASLAN Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023. View our ASLN earnings forecast. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.80) by $0.69. The firm earned $12 million during the quarter. When did ASLAN Pharmaceuticals' stock split? Shares of ASLAN Pharmaceuticals reverse split on Monday, March 13th 2023. The 1-5 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). When did ASLAN Pharmaceuticals IPO? (ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. What is ASLAN Pharmaceuticals' stock symbol? ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN." Who are ASLAN Pharmaceuticals' major shareholders? ASLAN Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (6.42%), Schonfeld Strategic Advisors LLC (0.33%), Renaissance Technologies LLC (0.18%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ASLAN Pharmaceuticals' stock price today? One share of ASLN stock can currently be purchased for approximately $2.01. How much money does ASLAN Pharmaceuticals make? ASLAN Pharmaceuticals (NASDAQ:ASLN) has a market capitalization of $32.86 million. The company earns $-51,380,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. How can I contact ASLAN Pharmaceuticals? ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The official website for the company is www.aslanpharma.com. The company can be reached via phone at 65-6817-9598, via email at investor@aslanpharma.com, or via fax at 65-6225-2419. This page (NASDAQ:ASLN) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.